To investigate the chronic effects of a novel thy rotropin-releasing hormone analog, lTP-2942 (N"'-[(IS, 2R)-2methyl-4-oxocyclopentylcarbonyll-L-histidyl-L-prolinamide monohydrate), on behavioral changes after stroke, the authors examined its effects on motor and neurologic deficits using a middle cerebral artery (MCA) occlusion model in rats. A left MCA was permanently occluded at a proximal site. From I week after occlusion, JTP-2942 was intravenously adminis tered once a day for 4 weeks. Sensorimotor performance was evaluated weekly for 10 weeks after the occlusion. The ability of the rat to maintain its body position on an inclined plane and neurologic examination based on hemiparesis and abnormal posture were examined, After all behavioral examinations were completed, the degree of shrinkage of the left hemisphere was measured. The ability of MCA-occluded rats to maintain body position on an inclined plane in the left-headed position was significantly lower than that of sham-operated rats throughout the test period. JTP-2942 gradually improved this deficit dose dependently, and a dose of 0.03 mg/kg of lTP-2942 signifi cantly improved performance to the levels of the sham operated rats. Neurologic deficits were also observed in MCA occluded rats, JTP-2942 also significantly improved these defi-
Patients with cerebrovascular disease may exhibit neu rologic symptoms such as hemiplegia as well as cogni tive disturbances (Caplan et aI., 1985 (Caplan et aI., , 1990 . Pathologic and functional changes not only during the acute phase but also during the subacute and chronic phases of focal cerebral ischemia have been extensively investigated (O'Brien et aI., 1974; Ginsberg et aI., 1977; Hayakawa and Waltz, 1975; Tamura et aI., 1980; Tamura et aI., cits dose dependently. On the other hand, CDP-choline (500 mg/kg, administered intravenously), a therapeutic agent for the disturbance of consciousness and hemiparesis after stroke, im proved neurologic deficits but did not affect the motor deficits measured using the inclined plane. It is noteworthy that the effects of JTP-2942 on these deficits were observed 4 weeks after cessation of drug administration. Furthermore, there was no difference in the degree of shrinkage of the cerebrum among the MCA-occluded groups. In the present study, long-lasting improving effects of lTP-2942 on the impairment of motor and neurologic functions were observed in rats with MCA occlu sion, which continued after cessation of drug administration and which were not attributable to a reduction in ipsilateral cerebral shrinkage. It is considered that the effect of lTP-2942 on functional recovery is attributable to the activation of sub stitutive functions such as neuronal reconstruction. These phar macologic properties of JTP-2942 may be of interest for the treatment of patients with motor and neurologic deficits during the chronic or subacute phase of stroke. Key Words: Focal cerebral ischemia-Middle cerebral artery occlusion-Inclined plane-Neurologic examination-Thyrotropin-releasing hor mone-lTP-2942.
1981a,b; Tamura et aI., 1985; Yamamoto et aI., 1988; Yamamoto et aI., 1989a,b; Markgraf et aI., 1992; Wahl et aI., 1992; Okada et aI., 1995; Yonemori et aI., 1996; Yonemori et aI., 1998) , However, for the development of therapeutic agents, there are only a few reports that evaluate the effect on motor or neurologic deficits during subacute or chronic phase of cerebral ischemia (Yama moto et aI., 1989a,b) .
Thyrotropin-releasing hormone (TRH: L-pyroglutamyl L-histidyl-L-prolinamide) is one agent expected to im prove symptoms that occur during the subacute or chronic phase of cerebral ischemia (Yamamoto et aI., 1989b) . TRH and its receptor are widely distributed in the central nervous system (Boler et aI., 1969; Brown stein et aI., 1974; Morley, 1979; Yarbrough, 1979; Em-son et aI., 1981; Pilotte et aI., 1984) , and it is considered that TRH plays an important role in the . However, its activity rapidly disappears because of its short half-life. JTP-2942 (N'" -[( 1 S,2R)-2-methyl-4-oxocyclopentylcar bonyIJ-L-histidyl-L-prolinamide monohydrate; Fig. I A) is a novel TRH analog in which the pyroglutamyl residue is replaced with methyl-oxocyclopentan and which is resistant to the specific TRH degradation enzyme, pyro glutamyl aminopeptidase II (Haruta et aI., 1991) . It has a more potent and longer lasting antagonistic effect against reserpine-induced hypothermia than TRH (Matsushita et aI., 1993 (Matsushita et aI., , 1995a , an antagonistic effect against pento barbital-induced anesthesia (Matsushita et aI., 1995b) , activation of electroencephalography (Yonemori et aI., 1992) , and an acetylcholine-releasing action (Toide et aI., 1993) . JTP-2942 also improved cognitive impairment in various animal models (Uemura et aI., 1993; Yamada et aI., 1993) . Recently, Katsumata et ai. (l996a, b) con firmed that JTP-2942 improved local cerebral blood flow and local glucose utilization in rats with cerebral isch emia in acute and chronic phase models. Thus, it would be interesting to ascertain whether or not lTP-2942 might be an effective drug for the treatment of neuro logic deficits after cerebral ischemia, particularly during the chronic phase.
The present study was performed to investigate the effects of lTP-2942 on motor and neurologic deficits during the subacute and chronic phase of focal cerebral ischemia using an middle cerebral artery (MCA) occlu sion model in rats and compared the effects of JTP-2942 with the effect of CDP-choline, a therapeutic agent for the disturbance of consciousness and hemiparesis after stroke (D'Orlando and Sandage., 1995; Secades and Frontera, 1995) .
METHODS

Surgical procedure
This experiment complied with the Guidelines of Animal Experimentation of the Teikyo University School of Medicine. Male Wi star rats (Sic, Shizuoka, Japan), 10 weeks of age and weighing 250 to 310 g, were anesthetized with I to 2% halo thane and the left MCA was permanently occluded at a proxi mal site using a microbipolar coagulator (Tamura et aI., 1981a; Yamamoto et aI., 1988) . After the incision was sutured, the rats were allowed free access to laboratory chow and water. Sham operated rats were subjected only to exposure of the MCA.
Drugs lTP-2942 (Lot Q; Central Pharmaceutical Research Institute, Japan Tobacco Inc.) was dissolved in physiologic saline (Otsuka Pharmaceutical Co., Ltd.) for intravenous administra tion at a dose of 1.0 mL/kg. For CDP-choline, nicholine H 25% solution for injection (Takeda Chemical Industries, Ltd.) was used at a dose of 2.0 mLlkg.
Behavioral examination
Inclined plane test. We evaluated the motor performance of the rats using an inclined plane (model SN-453, Shinano Co. Ltd., Tokyo, Japan), once a week for 9 weeks from 1 week after surgery according to the method described by Yonemori et al. (1998) . The sliding apparatus had a 60 x 40 cm stainless steel plane that could be inclined at an angle of 0° (horizontal) to 60°. Each rat was initially placed on a 30° inclined plane in the left-headed position (right side up orientation), right-headed position (left side up orientation), or up-headed position (head up orientation), and the angle of the inclined plane was in creased at a rate of 2°/s from 30 to 60°. The maximum angle was then determined at the moment when a limb of the rat slipped to maintain body position. The test was carried out three times for each head position and averaged. Each trial was carried out at I-minute intervals. During this time the rat was returned to a cage filled with dry wood chips, which were used to wipe and dry the urine and feces from the limbs and body so as not to influence the friction coefficient. Trials in which the rat turned its body uphill without slipping movement of a limb were not included.
Neurologic examination. We evaluated the sensorimotor per formance in the rats using a neurologic deficit score based on the detection of hemiparesis and abnormal posture. The right hind limb of each rat was extended gently with round-tipped forceps and the flexor response was evaluated as 0 (normal), 1 (slight deficit), 2 (moderate deficit), or 3 (severe deficit). For the assessment of posture, the rats were suspended by the tail, and forelimb flexion and body twisting were evaluated as 0 (normal), I (slight twisting), 2 (marked twisting), or 3 (marked twisting and forelimb flexion).
Passive avoidance task. The rats were tested using a step through type of passive avoidance task (Jarvik & Kopp, 1967; Yamamoto et aI., 1988) . The apparatus (Neuroscience Inc., Tokyo, Japan) consisted of two compartments: an illuminated chamber (10 cm x 30 cm) and a dark one (30 cm x 30 cm). The rats initially underwent habituation by placing them in the il luminated chamber, and a door between the chambers was then opened so that they could enter the dark chamber. In the ac quisition trial, the rats performed the same task, but a 0.60-mA foot shock was delivered through the grid floor for 1 second once they entered the dark chamber. Retention trials were per formed without foot shock 1 day after the acquisition trial. The step-through latency was recorded to a maximum of 300 sec onds.
Experimental procedure
The general protocol of this experiment is shown in Fig. 1 B. The MCAs of 50 rats were occluded and 7 rats were sham operated. MCA-occluded rats whose total neurologic score at 1 week after operation was 3 to 4 were selected, and these rats received JTP-2942 (0.003 mg/kg, n = 10; 0.01 mg/kg, n = 10; 0.03 mg/kg, n = 10), CDP-choline (500 mg/kg, n = 10), or saline (n = 10) intravenously from 1 week after operation once a day for 4 weeks. The sham-operated group (n = 7) was given only physiologic saline intravenously. Neurologic examination and the inclined plane test were performed once a week for 8 weeks, and the passive avoidance test was performed 2 weeks after operation. All behavioral tests were performed blindly before daily drug administration.
Histopathology
After the behavioral studies were completed, the rats were anesthetized and fixed by perfusion with 10% formaldehyde in 0. 1 mollL phosphate buffer, and the brains were removed. Five coronal blocks (2 mm thick) were cut from 12.2 to 4.2 mm anterior to the interaural line, according to the brain atlas of Paxinos and Watson (1986) , and embedded in paraffin. Then, 4-f.1m sections were cut from each block and stained with he matoxylin and eosin. The area of each cerebral hemisphere was determined on individual sections using a digitizer (Luzex FS, Nireco, Tokyo, Japan), and the volume of each hemisphere was calculated from the individual areas. The infarcted volume was calculated by subtracting the volume of the left hemisphere from that of the right hemisphere.
Statistical analysis
The values are expressed as mean ± SD for all parameters. To analyze parametric data, repeated measures of analysis of variance (ANOVA) followed by Tukey's test or Student's t test was used. When dealing with nonparametric data, Kruskal Wallis test followed by Mann-Whitney U test was applied.
RESULTS
General behavior
Eight rats with MCA occlusion died (vehicle, 2; lTP-2942 0.003, 2; lTP-2942 0.01, 1; lTP-2942 0.03, I; CDP-choline, 2) with no significant differences among the groups. There was also no difference in body weight among the six groups (group: F5,43 = 1.865, P = 0.121; time: F9.387 = 34.164, P < 0.001; group*time: F45.387 = 1.087, P = 0.331; two-factor ANOVA for repeated mea surements).
Inclined plane test
The motor performance using the inclined plane test was evaluated once a week for 8 weeks. Figure 2 shows the results of the test. The maximum angles at which body position was maintained in the sham-operated rats were 43.8 ± 1.4°, 43.3 ± 1.7°, and 42.9 ± 1.7° for left-, right-, and up-headed initial body positions, respectively, at 1 week after surgery. When compared to the sham operated rats, the MCA-occluded rats exhibited disturbed performance in this task. First, for the left-headed initial position, the maximum angle to hold position, 36.8 ± 0.8° at 1 week after MCA occlusion, significantly de creased compared with that of the sham-operated rats (P < 0.01, Tukey's test). This decrease was detected throughout the test period ( Fig. 2A) . Administration of lTP-2942 (0.01 to 0.03 mg/kg, administered intrave- nous1y) significantly improved this deficit in a time-and dose-dependent manner compared to the vehicle group, and the maximum angle at which body position was maintained on the inclined plane increased to that of sham-operated rats at 3 to 5 weeks after the start of the drug administration (group: Fs,43 = 117.90, P < 0.001; time:F8.344 = 57.19, P<0.001;groupxtime:F4o.344 = 11.50, P < 0.001; two-factor ANOV A for repeated mea surements). It is noteworthy that this improvement still persisted 4 weeks after the cessation of ITP-2942 treat ment. On the other hand, CDP-choline did not improve the deficit throughout the test period. Second, for the right-headed initial position, the maxi mum angle was 41.2 ± 2.1° (mean ± SD) at I week after MCA occlusion which was similar to that of the sham operated rats. However, the maximum angle gradually decreased to below 40° after 3 weeks (Fig. 2B) . The maximum angle at which the ITP-2942 (0.01 to 0.03 mg/kg, administered intravenously)-treated rats could maintain their body position on the inclined plane was over 40° throughout the test period and did not decrease even after the cessation of JTP-2942 treatment. This angle was similar to the maximum angle of the sham operated group. The angle of the CDP-choline-treated group decreased to below 40° after 3 weeks and did not improve throughout the test period (group: F S .43 = 62.20, P < 0.001; time: F S • 344 = 2.08, P < 0.05; group x time: F40.344 = 5.60, P < 0.001; two-factor ANOVA for repeated measurements).
Third, for the up-headed initial position, the level of performance was the same as that for the left-headed position (Fig. 2C) . The sham-operated rats did not ex hibit any deficit in ability throughout the test period (group: F S .43 8 = 81.35, P < 0.001; time: F S , 344 = 19, P < 0.001; group x time: F40,344 = 11.50, P < 0.001; two-factor ANOV A for repeated measurements). Figure 3 shows the results of the neurologic examina tion. The MCA-occluded rats had a significantly higher neurologic deficit score at 1 week after MCA occlusion than the sham-operated rats (P < 0.01, Kruskal-Wallis followed by Mann-Whitney U test). MCA occlusion also significantly disturbed both the posture and the flexor response of the contralateral hindlimb (P < 0.01, Mann Whitney U test). Although the neurologic deficit scores showed gradual recovery, MCA-occluded rats had sig nificantly higher neurologic deficit scores than sham operated rats even at 9 weeks after surgery. Administra tion of ITP-2942 (0.003 to 0.03 mg/kg, intravenously) significantly improved this deficit in a time-and dose dependent manner compared to the vehicle group. CDP choline (500 mg/kg, administered intravenously) also improved this deficit.
Neurologic examination
Passive avoidance task
The step-through test was performed 2 weeks after MCA occlusion. The retention latency of the sham operated rats was 300 seconds, which indicated that all these rats performed this test well (Fig. 4) . On the other hand, the MCA-occluded rats did not; the retention la tency of the vehicle group was 129 ± 127 seconds, which .2_ 2 0 -
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OQ. to the vehicle group. CDP-choline (intravenous 500 mg/ kg) also improved this deficit.
Histology
Infarcted volumes were calculated from the ipsilateral to the contralateral hemisphere volume in the coronal slices from interaural 12.2 to 4.2 mm. The infarcted vol ume of the MCA-occluded group was 154 ± 30 mm 3
which was significantly increased compared to that of the sham-operated group (15 ± 30 mm 3 ). Administration of lTP-2942 (0.003 to 0.03 mg/kg) or CDP-choline (500 mg/kg) did not affect the infarcted volumes compared to that of the vehicle group (AN OVA followed by Tukey's test; Fig. 5 ).
DISCUSSION
Patients with cerebrovascular disease frequently ex hibit various clinical symptoms, including motor deficits such as neurologic disorder, and cognitive disturbances as well as psychosomatic manifestations (Caplan et aI., 1985 (Caplan et aI., , 1990 . Motor deficits comprise the core symptoms and are the most important targets for clinical therapy. However, there are few effective drugs for these deficits.
Thyrotropin-releasing hormone (TRH: L-pyroglutamyl L-histidyl-L-prolinamide) is one agent which is expected J Cereb Blood Flow Metab. Vol. 20, No.1, 2000 to improve symptoms during the subacute or chronic phase of cerebral ischemia (Yamamoto et aI., 1989b) , TRH is widely distributed in the central nervous system, including the amygdala, medulla, cortex, septum, and hippocampus (Boler et aI., 1969; Brownstein et aI., 1974; Morley, 1979; Yarbrough, 1979; Emson et aI., 1981) . TRH receptors are also localized in many brain regions, including the amygdala, hippocampus, hypothalamus, and cortex (Pilotte et aI., 1984) . Experimentally, TRH antagonizes hypothermia and anesthesia, activates elec troencephalography (Breese et aI., 1975; Clark and Lip ton, 1983; Yamamura et aI., 1990; Yamamura et aI., 1991) , promotes acetylcholine release (Giovannini et aI., 1991) , and increases cerebral blood flow (Koskinnen and Bill, 1984; Koskinnen and Sperber, 1986; Koskinnen, 1986) . However, TRH is well known to be rapidly me tabolized in the body (Bassiri and Utiger, 1973; Yoko hama et aI., 1984) . JTP-2942 (N"-[(lS,2R)-2-methyl-4oxocyclopenty lcarbony I] -L-histidy 1-L-prolinamide monohydrate; Fig. lA) , in which the pyroglutamyl resi due is replaced with methyl-oxocyclopentan, is resistant to the degradation enzyme of TRH in the brain, pyroglu tamyl aminopeptidase II (Haruta et aI., 1991) . It has a more potent and longer lasting antagonistic effect against reserpine-induced hypothermia as compared to TRH (Matsushita et aI., 1993 (Matsushita et aI., , 1995a , an antagonistic ef fect against pentobarbital-induced anesthesia (Mat sushita et aI., 1995b) , activation of electroencephalogra phy (Yonemori et aI., 1992) , and an acety1choline- Each column represents the mean ± SD (n = 7 to 9). There were no significant differences among the MCA-occluded groups.
releasing action (To ide et aI., 1993) . However, lTP-2942 does not affect the blood pressure, heart rate, and glu cose level at a dose of 0.03 mg/kg or less (unpublished data). The present study was performed to investigate the effect of lTP-2942 on motor and neurologic deficits dur ing the subacute and chronic phases of focal cerebral ischemia because development of a delayed treatment is very important in stroke patients. Yamamoto et aI. (1989b) reported that a TRH analog improved behavioral response in a model of focal ischemia when the drug administration was started 1 week after ischemia. Simi larly, the administration of lTP-2942 was started 1 week after ischemia in this study. We used a proximal MCA occlusion model in rats as reported by Tamura et aI. (Tamura et aI., 1981a,b; Yamamoto et ai. 1988 ) because of the constant size of the infarct in this model and be cause of the similarities between the anatomy of the cra nial circulation in the rat and humans (Yamori et aI., 1976) . In the inclined plane test, the maximum angle at which the body position was maintained on the plane was improved when JTP-2942 was administered for 4 weeks. On the other hand, CDP-choline, which is widely used as an agent for hemiparesis and disturbance of con sciousness (D'Orlando and Sandage, 1995; Secades and Frontera, 1995) , did not affect the maximum angle of the inclined plane. Impaired sensorimotor performance, based on the evaluation of posture and hemiparesis de veloped by Bederson et aI. (1986) , and the passive avoid ance task were improved with administration of JTP-2942 and CDP-choline. The improvements were not re lated to a reduction in the infarcted area.
Because the inclined plane test serves as an indicator of the muscle strength in MCA-occluded rats (Yonemori et aI., 1998) , the improvement effect of lTP-2942 ob served in the inclined plane test was considered to reflect an improvement in the muscle weakness caused by MCA occlusion. On the other hand, inasmuch as CDP-choline did not affect the angle of the inclined plane, it is con sidered to be effective in improving sensorimotor perfor mance but not muscle strength. Thus, it is considered that JTP-2942 may aid in the recovery of motor deficits after cerebral ischemia because of muscle weakness, which constitutes a common complaint after stroke in humans. Additionally, JTP-2942 was effective in the improve ment of neurologic performance and the passive avoid ance task in rats, as was CDP-choline, indicating that JTP-2942 might be effective for treating memory distur bance.
It is noteworthy that the effect on muscle strength detected in the inclined plane test still persisted after the cessation of JTP-2942 administration. This indicates that JTP-2942 caused not only the activation of damaged neuronal networks but also structural changes. This is first because the measurement was performed before daily administration of drugs and second because it was considered that JTP-2942 did not remain in the rats 4 weeks after cessation of drug administration (tl/2 of JTP-2942 is about 30 minutes in rats). This indicated that although lTP-2942 directly activated cholinergic, dopa minergic, noradrenergic, serotonergic neurons, and other neuronal types for several hours after administration (Shinoda et aI., 1992; Toide et ai. , 1993) , these activa tions did not directly affect the motor performance on the inclined plane. On the other hand, administration of JTP-2942 was only started 1 week after MCA occlusion, when the presence of an infarcted area was confirmed. It is not considered that lTP-2942 administration in this protocol reduced the size of infarct. Indeed, the shrink age observed in JTP-2942-treated groups was not differ ent from that in the vehicle-treated group in this study. From this point of view we concluded that there may be some mechanism for JTP-2942 to improve the motor deficit caused by MCA occlusion and that this may be associated with plastic changes, such as changes in syn aptic connections or activation of a compensation mechanism. In support of this idea it has been reported that TRH promotes neurite development in cultured neu rons (Schmidt-Achert et aI., 1984; Iwasaki et aI., 1992) , and our findings show that lTP-2942 has a similar effect (data not shown). Such improvement associated with synaptic connection changes or activation of a compen sation mechanism may involve increased metabolic turn over related to oxygen and glucose supply. Recently, Katsumata et ai. (1996a,b) confirmed that lTP-2942 im proved local cerebral blood flow and local glucose uti lization in rats with cerebral ischemia.
CDP-choline, which is approved in Europe and Japan for treatment of patients suffering from stroke, head trauma, and other neurologic disorders (D'Orlando and Sandage, 1995; Secades and Frontera, 1995) , improved sensorimotor performance, based on posture and hemi paresis evaluations, and improved performance in the passive avoidance task but did not affect the angle on the inclined plane, an indicator for muscle strength. CDP choline may thus affect sensorimotor performance but not muscle strength. In this regard, JTP-2942 is expected to serve as an agent to improve not only sensorimotor performance but also muscle strength, which is the most important target for clinical therapy.
In conclusion, a novel TRH analog, lTP-2942, im proved motor deficits, particularly muscle strength, as well as sensorimotor performance. These effects were not attributable to a change in the size of the infarct and were not diminished 4 weeks after cessation of drug administration. The mechanisms of the improving ef fect of JTP-2942 may be associated with changes in syn aptic connections or activation of a compensation mechanism.
